Why ImmunityBio’s ANKTIVA cost analysis could intensify the bladder cancer value debate
Bladder cancer drugs face a value test. ImmunityBio’s ANKTIVA analysis raises new questions on cost, response durability and access.
Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise
ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.
Can Ferring turn real-world ADSTILADRIN use into a broader NMIBC treatment strategy?
Bladder-sparing therapy needs better sequencing. Ferring’s ADSTILADRIN re-induction signal raises hope, but durability is the real test.
Macau clears ImmunityBio’s ANKTIVA for BCG-unresponsive NMIBC, opening Asia market amid commercialization test
ImmunityBio’s first Asia approval for ANKTIVA in BCG-unresponsive bladder cancer: what the Macau clearance means for its global strategy. Read the analysis.
ImmunityBio resubmits FDA application for ANKTIVA in bladder cancer after agency requests updated efficacy data
ImmunityBio has resubmitted its supplemental biologics license application to the U.S. Food and Drug Administration for ANKTIVA (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guerin for BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors, after the agency requested updated long-term efficacy data in March 2026. The resubmission follows a regulatory exchange that began in January […]